{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:14:19Z","timestamp":1789416859328,"version":"build-2803163510"},"reference-count":32,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA047904"],"award-info":[{"award-number":["P30CA047904"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA254865"],"award-info":[{"award-number":["P50CA254865"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD028483"],"award-info":[{"award-number":["S10OD028483"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1CA186690"],"award-info":[{"award-number":["UM1CA186690"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,9,7]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>\n                    Acral melanoma (AM) has distinct characteristics as compared with cutaneous melanoma and exhibits poor response to immune checkpoint inhibitors (ICIs). Tumor-intrinsic mechanisms of immune exclusion have been identified in many cancers but less studied in AM. We characterized clinically annotated tumors from patients diagnosed with AM at our institution in correlation with ICI response using whole transcriptome RNAseq, whole exome sequencing, CD8 immunohistochemistry, and multispectral immunofluorescence imaging. A defined interferon-\u03b3-associated T cell-inflamed gene signature was used to categorize tumors into non-T cell-inflamed and T cell-inflamed phenotypes. In combination with AM tumors from two published studies, we systematically assessed the immune landscape of AM and detected differential gene expression and pathway activation in a non-T cell-inflamed tumor microenvironment (TME). Two single-cell(sc) RNAseq AM cohorts and 11 bulk RNAseq cohorts of various tumor types were used for independent validation on pathways associated with lack of ICI response. In total, 892 specimens were included in this study. 72.5% of AM tumors showed low expression of the T cell-inflamed gene signature, with 23.9% of total tumors categorized as the non-T cell-inflamed phenotype. Patients of low CD3\n                    <jats:sup>+<\/jats:sup>\n                    CD8\n                    <jats:sup>+<\/jats:sup>\n                    PD1\n                    <jats:sup>+<\/jats:sup>\n                    intratumoral T cell density showed poor prognosis. We identified 11 oncogenic pathways significantly upregulated in non-T cell-inflamed relative to T cell-inflamed TME shared across all three acral cohorts (MYC, HGF, MITF, VEGF, EGFR, SP1, ERBB2, TFEB, SREBF1, SOX2, and CCND1). scRNAseq analysis revealed that tumor cell-expressing pathway scores were significantly higher in low versus high T cell-infiltrated AM tumors. We further demonstrated that the 11 pathways were enriched in ICI non-responders compared with responders across cancers, including AM, cutaneous melanoma, triple-negative breast cancer, and non-small cell lung cancer. Pathway activation was associated with low expression of interferon stimulated genes, suggesting suppression of antigen presentation. Across the 11 pathways, fatty acid synthase and CXCL8 were unifying downstream target molecules suggesting potential nodes for therapeutic intervention. A unique set of pathways is associated with immune exclusion and ICI resistance in AM. These data may inform immunotherapy combinations for immediate clinical translation.\n                  <\/jats:p>","DOI":"10.1136\/jitc-2023-007567","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T20:51:19Z","timestamp":1697748679000},"page":"e007567","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04572451","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ryan C","family":"Augustin","sequence":"first","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"},{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"},{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Newman","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aofei","family":"Li","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"},{"name":"Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Joy","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Lyons","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary P","family":"Pham","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lucas","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"},{"name":"Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Smith","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Sander","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Isett","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7846-8055","authenticated-orcid":false,"given":"Diwakar","family":"Davar","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"},{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0138-1664","authenticated-orcid":false,"given":"Yana G","family":"Najjar","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"},{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassane M","family":"Zarour","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"},{"name":"Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"},{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-4908","authenticated-orcid":false,"given":"Jason John","family":"Luke","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"},{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6105-1704","authenticated-orcid":false,"given":"Riyue","family":"Bao","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"},{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"2025100313395264000_11.10.e007567.1","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12885"},{"key":"2025100313395264000_11.10.e007567.2","doi-asserted-by":"publisher","DOI":"10.1038\/nature22071"},{"key":"2025100313395264000_11.10.e007567.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.031"},{"key":"2025100313395264000_11.10.e007567.4","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-21-3145","article-title":"Single-cell characterization of the cellular landscape of Acral Melanoma identifies novel targets for Immunotherapy","volume":"28","author":"Li","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"2025100313395264000_11.10.e007567.5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2025100313395264000_11.10.e007567.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1609376113"},{"key":"2025100313395264000_11.10.e007567.7","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-020-00787-6","article-title":"Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types","volume":"12","author":"Bao","year":"2020","journal-title":"Genome Med"},{"key":"2025100313395264000_11.10.e007567.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1942"},{"key":"2025100313395264000_11.10.e007567.9","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.78616","article-title":"Mapping the single-cell landscape of Acral Melanoma and analysis of the molecular regulatory network of the tumor Microenvironments","volume":"11","author":"He","year":"2022","journal-title":"Elife"},{"key":"2025100313395264000_11.10.e007567.10","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt703"},{"key":"2025100313395264000_11.10.e007567.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2017.03.004"},{"key":"2025100313395264000_11.10.e007567.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0403-1"},{"key":"2025100313395264000_11.10.e007567.13","first-page":"1","article-title":"The effects of MYC on tumor immunity and Immunotherapy","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov"},{"key":"2025100313395264000_11.10.e007567.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2003648","article-title":"A direct link between MITF, innate immunity, and hair graying","volume":"16","author":"Harris","year":"2018","journal-title":"PLOS Biol"},{"key":"2025100313395264000_11.10.e007567.15","doi-asserted-by":"crossref","unstructured":"Zhu H , Liu Y , Liu D , et al . Role of TGF\u03b23-Smads-Sp1 axis in Dcr3-mediated immune escape of hepatocellular carcinoma. Oncogenesis 2019;8. doi:10.1038\/s41389-019-0152-0","DOI":"10.1038\/s41389-019-0152-0"},{"key":"2025100313395264000_11.10.e007567.16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000543","article-title":"TFEB is a master regulator of tumor-associated Macrophages in breast cancer","volume":"8","author":"Li","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100313395264000_11.10.e007567.17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001037","article-title":"Sox2 promotes resistance of Melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA","volume":"8","author":"Wu","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100313395264000_11.10.e007567.18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01620"},{"key":"2025100313395264000_11.10.e007567.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.06.017"},{"key":"2025100313395264000_11.10.e007567.20","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3436"},{"key":"2025100313395264000_11.10.e007567.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131241","article-title":"Dual fatty acid synthase and Her2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-Her2 drugs","volume":"10","author":"Blancafort","year":"2015","journal-title":"PLoS One"},{"key":"2025100313395264000_11.10.e007567.22","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0689"},{"key":"2025100313395264000_11.10.e007567.23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02927","article-title":"Ovarian cancer-intrinsic fatty acid synthase prevents anti-tumor immunity by disrupting tumor-infiltrating Dendritic cells","volume":"9","author":"Jiang","year":"2018","journal-title":"Front Immunol"},{"key":"2025100313395264000_11.10.e007567.24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.836939","article-title":"Fatty acid synthase is the key regulator of fatty acid metabolism and is related to Immunotherapy in bladder cancer","volume":"13","author":"Xiong","year":"2022","journal-title":"Front Immunol"},{"key":"2025100313395264000_11.10.e007567.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0856-x"},{"key":"2025100313395264000_11.10.e007567.26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","article-title":"High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade","volume":"26","author":"Yuen","year":"2020","journal-title":"Nature Medicine"},{"key":"2025100313395264000_11.10.e007567.27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx190"},{"key":"2025100313395264000_11.10.e007567.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2463"},{"key":"2025100313395264000_11.10.e007567.29","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3329","article-title":"Co-expression of Her2 and Her3 receptor tyrosine Kinases enhances invasion of breast cells via stimulation of Interleukin-8 Autocrine secretion","volume":"14","author":"Aceto","year":"2012","journal-title":"Breast Cancer Res"},{"key":"2025100313395264000_11.10.e007567.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1063"},{"key":"2025100313395264000_11.10.e007567.31","doi-asserted-by":"crossref","unstructured":"Davar D , Simonelli M , Gutierrez M , et al . 394\u2005Interleukin-8\u2013neutralizing Monoclonal antibody BMS-986253 plus Nivolumab (NIVO) in biomarker-enriched, primarily anti\u2013PD-(L)1\u2013experienced patients with advanced cancer: initial phase 1 results. 35th Anniversary Annual Meeting (SITC 2020); November 2020 doi:10.1136\/jitc-2020-SITC2020.0394","DOI":"10.1136\/jitc-2020-SITC2020.0394"},{"key":"2025100313395264000_11.10.e007567.32","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162260","article-title":"Partial tumor irradiation plus Pembrolizumab in treating large advanced solid tumor metastases","volume":"133","author":"Korpics","year":"2023","journal-title":"The Journal of Clinical Investigation"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:40:01Z","timestamp":1759524001000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,19]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/jitc-2023-007567"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007567","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.08.24.554717","asserted-by":"object"}]},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}